Equities Analysts Set Expectations for CRSP FY2026 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will earn ($6.73) per share for the year. Cantor Fitzgerald has a "Neutral" rating on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.

CRSP has been the topic of several other reports. Citigroup cut their target price on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research report on Tuesday, February 18th. Morgan Stanley upped their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a research note on Friday, February 14th. Evercore ISI raised CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price objective for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Stifel Nicolaus decreased their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a report on Thursday, February 13th. Finally, Needham & Company LLC restated a "buy" rating and issued a $81.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP traded up $0.08 during trading hours on Tuesday, reaching $41.36. 2,016,735 shares of the company were exchanged, compared to its average volume of 1,750,748. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of -9.46 and a beta of 1.75. The stock has a 50 day simple moving average of $37.75 and a 200 day simple moving average of $40.95. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $65.39.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter last year, the firm earned ($1.43) earnings per share. CRISPR Therapeutics's revenue for the quarter was up 71.6% on a year-over-year basis.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Kestra Private Wealth Services LLC increased its stake in shares of CRISPR Therapeutics by 1.5% in the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock worth $812,000 after buying an additional 310 shares during the last quarter. Capital Advisors Inc. OK grew its holdings in CRISPR Therapeutics by 3.2% during the 4th quarter. Capital Advisors Inc. OK now owns 310,270 shares of the company's stock worth $12,212,000 after acquiring an additional 9,681 shares in the last quarter. Van ECK Associates Corp increased its position in shares of CRISPR Therapeutics by 5,269.3% in the 4th quarter. Van ECK Associates Corp now owns 83,010 shares of the company's stock worth $3,267,000 after purchasing an additional 81,464 shares during the last quarter. Congress Asset Management Co. increased its position in shares of CRISPR Therapeutics by 4.5% in the 4th quarter. Congress Asset Management Co. now owns 68,739 shares of the company's stock worth $2,706,000 after purchasing an additional 2,971 shares during the last quarter. Finally, Allworth Financial LP raised its stake in shares of CRISPR Therapeutics by 2,117.4% in the 4th quarter. Allworth Financial LP now owns 15,078 shares of the company's stock valued at $593,000 after purchasing an additional 14,398 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Naimish Patel sold 3,932 shares of the stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the transaction, the insider now owns 6,068 shares of the company's stock, valued at approximately $218,083.92. This represents a 39.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 4.30% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.